Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Cash from Financing Activities (2016 - 2025)

Eledon Pharmaceuticals filings provide 5 years of Cash from Financing Activities readings, the most recent being $750000.0 for Q4 2017.

  • On a quarterly basis, Cash from Financing Activities changed N/A to $750000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $7.9 million, a 168.57% increase, with the full-year FY2025 number at $53.8 million, down 59.7% from a year prior.
  • Cash from Financing Activities hit $750000.0 in Q4 2017 for Eledon Pharmaceuticals, down from $6.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $88.9 million in Q3 2014 to a low of -$437000.0 in Q2 2014.
  • Median Cash from Financing Activities over the past 5 years was $311000.0 (2015), compared with a mean of $8.7 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 99.79% in 2015 and later surged 1438.83% in 2016.
  • Eledon Pharmaceuticals' Cash from Financing Activities stood at $15.5 million in 2013, then crashed by 59.57% to $6.3 million in 2014, then tumbled by 99.23% to $48000.0 in 2015, then soared by 5927.08% to $2.9 million in 2016, then plummeted by 74.08% to $750000.0 in 2017.
  • The last three reported values for Cash from Financing Activities were $750000.0 (Q4 2017), $6.7 million (Q2 2017), and $400000.0 (Q1 2017) per Business Quant data.